Table 2.

Biodistribution of ^99mTc(CO)₃-NOTA-GGNle-CycMSH_hex on B16/F10 melanoma-bearing C57 mice. The data were presented as percent injected dose/gram or as percent injected dose (Mean ± SD, n = 4)

Tissues	0.5 h	2 ha	4 h	24 h	2 h NDP blockade
	Percent injected dose/gram (%ID/g)
Tumor	16.07 ± 4.47	19.76 ± 3.62	11.30 ± 2.81	3.16 ± 2.28	0.80 ± 0.11*
Brain	0.13 ± 0.02	0.03 ± 0.01	0.01 ± 0.01	0.01 ± 0.01	0.04 ±.0.03
Blood	1.44 ± 0.33	2.19 ± 0.73	0.11 ± 0.06	0.03 ± 0.05	0.22 ± 0.18
Heart	0.74 ± 0.20	0.11 ± 0.07	0.07 ± 0.03	0.08 ± 0.07	0.17 ± 0.05
Lung	2.11 ± 0.65	0.28 ± 0.17	0.18 ± 0.05	0.03 ± 0.03	0.44 ± 0.26
Liver	2.32 ± 0.20	1.57 ± 0.32	1.43 ± 0.31	0.53 ± 0.17	4.32 ± 1.34
Spleen	0.76 ± 0.48	0.38 ± 0.20	0.11 ± 0.05	0.19 ± 0.25	0.78 ± 0.44
Stomach	1.11 ± 0.42	0.50 ± 0.37	0.25 ± 0.06	0.06 ± 0.07	1.02 ± 0.36
Kidneys	7.16 ± 0.79	1.59 ± 0.52	0.81 ± 0.21	0.23 ± 0.19	3.07 ± 0.61*
Muscle	0.19 ± 0.06	0.09 ± 0.06	0.01 ± 0.01	0.03 ± 0.04	0.08 ± 0.08
Pancreas	0.29 ± 0.10	0.11 ± 0.06	0.01 ± 0.01	0.03 ± 0.05	0.14 ± 0.17
Bone	0.82 ± 0.41	0.29 ± 0.09	0.07 ± 0.06	0.01 ± 0.00	0.16 ± 0.05
Skin	1.89 ± 0.44	0.35 ± 0.14	0.07 ± 0.07	0.12 ± 0.12	0.12 ± 0.18
	Percent injected dose (%ID)
Intestines	2.41 ± 0.31	2.95 ± 0.25	2.60 ± 0.28	0.40 ± 0.40	4.18 ± 1.90
Urine	80.18 ± 2.97	89.50 ± 2.10	92.88 ± 0.42	97.76 ± 0.56	89.26 ± 2.78
	Uptake ratio of tumor/normal tissue
Tumor/blood	11.16	9.02	102.64	105.33	3.64
Tumor/kidney	2.24	12.43	13.94	13.74	0.26
Tumor/lung	7.62	70.57	62.72	105.33	1.82
Tumor/liver	6.93	12.59	7.9	5.96	0.19
Tumor/muscle	84.58	219.56	1129.0	105.33	10.0
Tumor/skin	8.50	56.46	161.29	26.33	6.67

^a2 h Data was cited from Table 1 for comparison.

^*p<0.05 for determining significance of differences in tumor and kidney uptake between ^99mTc(CO)₃-NOTA-GGNle-CycMSH_hex with or without peptide blockade at 2 h post-injection.